{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:16:02Z","timestamp":1779228962903,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jhep.2016.02.044","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T20:01:59Z","timestamp":1457208119000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"title":["Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C"],"prefix":"10.1016","volume":"65","author":[{"given":"Aude","family":"Desnoyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Pospai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh Patrick","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Heurgu\u00e9-Berlot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achour","family":"Laradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Harent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Hillaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Zucman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Simonpoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Muret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucile","family":"Larrouy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Bernard Chabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.02.044_b0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2008.06.003","article-title":"Hepatitis C virus and kidney disease","volume":"49","author":"Martin","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0015","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ki.2013.455","article-title":"A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease","volume":"85","author":"Chen","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2016.02.044_b0020","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.02.044_b0025","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.044_b0030","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2014.01.012","article-title":"Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients","volume":"60","author":"Baid-Agrawal","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.565","article-title":"Hepatitis C virus infection in haemodialysis and kidney transplant patients","volume":"18","author":"Baid-Agrawal","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jhep.2016.02.044_b0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4254\/wjh.v7.i3.548","article-title":"Hepatitis C in hemodialysis patients","volume":"7","author":"Marinaki","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4254\/wjh.v7.i1.78","article-title":"Hepatitis C and kidney disease: an overview and approach to management","volume":"7","author":"Azmi","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2016.02.044_b0055","unstructured":"Sovaldi. 2015. Sofosbuvir. Summary of Product Characteristics, Gilead Sciences, Hayes, UK. Food & Drug Administration. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204671s004lbl.pdf. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0060","unstructured":"Rower J, Hodara A, Tise S, Everson G, Bushman L, Anderson P, et al. Intracellular pharmacokinetics of sofosbuvir in vivo (Abstract 81). In: 22nd Annual Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2015."},{"key":"10.1016\/j.jhep.2016.02.044_b0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tid.12348","article-title":"Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis","volume":"17","author":"Perumpail","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.044_b0070","unstructured":"Gane EJ, Robson RA, Bonacin M, Maliakkal B, Kirby B, Liu L, et al. Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. Hepatology. 2014;60 (Abstract 966). In: 65th Annual Meeting of the American Association for the Study of Liver diseases. Boston, USA; 2014."},{"key":"10.1016\/j.jhep.2016.02.044_b0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10620-015-3756-z","article-title":"A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis","volume":"61","author":"Perumpail","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2016.02.044_b0085","doi-asserted-by":"crossref","unstructured":"Nazario HE, Ndungu M, Modi A. Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR <30 mL\/min (Poster P0802). In: 50th International Liver Congress. Vienna, Austria; 2015.","DOI":"10.1016\/S0168-8278(15)31005-9"},{"key":"10.1016\/j.jhep.2016.02.044_b0090","doi-asserted-by":"crossref","unstructured":"Cornpropst MT, Denning JM, Clemons D, Marbury TC, Alcorn H, Smith WB, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977 (poster 1,101). In: 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain; 2012.","DOI":"10.1016\/S0168-8278(12)61113-1"},{"key":"10.1016\/j.jhep.2016.02.044_b0095","unstructured":"Harvoni. 2015. Sofosbuvir\/ledipasvir. Summary of Product Characteristics, Gilead Sciences, Hayes, UK. Food & Drug Administration. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205834s001lbl.pdf. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0100","unstructured":"AASLD\/IDSA\/IAS-USA. 2015. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http:\/\/www.hcvguidelines.org\/. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.044_b0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-5926-3-8","article-title":"Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C","volume":"3","author":"Poynard","year":"2004","journal-title":"Comp Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","article-title":"Liver EAftSot. EASL recommendations on treatment of hepatitis C 2014","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.044_b0125","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.jchromb.2009.10.013","article-title":"Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS\/MS","volume":"877","author":"Farnik","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jhep.2016.02.044_b0130","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.jhep.2016.02.044_b0135","unstructured":"French National Guidelines. 2013. Prise en charge m\u00e9dicale des personnes vivant avec le VIH: actualisation 2014 du rapport Morlat 2013. Available at: http:\/\/www.sante.gouv.fr\/IMG\/pdf\/experts-vih_actualisations2014.pdf. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0140","unstructured":"European medicines agency recommends avoidance of certain hepatitis C medicines and amiodarone together. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/04\/news_detail_002313.jsp&mid=WC0b01ac058004d5c1. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0145","unstructured":"Food & Drug Administration. Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm439484.htm. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0150","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1053\/j.gastro.2015.07.051","article-title":"Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge","volume":"149","author":"Renet","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.044_b0155","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMc1505967","article-title":"Bradyarrhythmias associated with sofosbuvir treatment","volume":"373","author":"Fontaine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.044_b0160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.02.044_b0165","unstructured":"Daklinza. 2015. Daclatasvir. Summary of Product Characteristics, Bristol Myers Squibb, New York City, NY, USA. Food & Drug Administration. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206843Orig1s000lbl.pdf. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0170","unstructured":"Olysio. 2015. Simeprevir. Summary of Product Characteristics, Janssen-Cilag, Titusville, NJ, USA. Food & Drug Administration. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205123s008lbl.pdf. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0175","unstructured":"Rebetol. Ribavirine. Summary of Product Characteristics, Merck Sharp & Dohme Corp, Whitehouse station, NJ, USA. Food & Drug Administration. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020903s053,021546s009lbl.pdf. Last accessed: January 2016."},{"key":"10.1016\/j.jhep.2016.02.044_b0180","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/jcph.346","article-title":"Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate\/ethinyl estradiol in HCV-uninfected female subjects","volume":"54","author":"German","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2016.02.044_b0185","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40261-014-0219-9","article-title":"The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus","volume":"34","author":"Eley","year":"2014","journal-title":"Clin Drug Invest"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816300101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816300101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T07:57:22Z","timestamp":1567670242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816300101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0168827816300101"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.044","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}